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Abstract
Background: Uncontrolled haemorrhage is still the leading cause of preventable death after trauma and the primary
focus of any treatment strategy should be related to early detection and control of blood loss including haemostasis.
Methods: For assessing management practices across six European level I trauma centres with academic interest and
research in the field of coagulopathy an online survey was conducted addressing local management practice for
bleeding trauma patients including algorithms for detection, management and monitoring coagulation disorders and
immediate interventions. Each centre provided their locally applied massive transfusion protocol.
Results: All participating trauma centres have developed and implemented a local algorithm and protocol for the
bleeding trauma patient. These are uniformly activated by clinical triggers and deactivated once the bleeding has
stopped according to clinical assessment in combination with laboratory signs of achieved haemostasis. The severity of
coagulopathy and shock is mostly assessed via standard coagulation tests and partially used extended viscoelastic tests.
All centres have implemented the immediate use of tranexamic acid. Initial resuscitation is started either pre-hospital or
after hospital admission by using transfusion packages with pre-fixed universal blood product combinations and ratios
following the concept of “damage control resuscitation” at which applied ratios substantially vary. Two centres initially
start with transfusion packages but with viscoelastic tests running in parallel to quickly allow a shift towards a
viscoelastic test-guided therapy.
Conclusion: Diversity in the management of bleeding trauma patients such as pre-hospital blood administration
and routinely performed viscoelastic tests exists even among level I trauma centres. The paucity of consensus
among these centres highlights the need for further primary research followed by clinical trials to improve the
evidence for sophisticated guidelines and strategies.
Introduction
Modern trauma care has demonstrated to lower mortality
by creating multidisciplinary evidence-based treatment al-
gorithms for the bleeding trauma patient, by creating
awareness among the involved medical specialties and by
improving mutual understanding [1, 2]. Several examples
have emphasized the value of treatment algorithms in
improving trauma care and, vice-versa, deviations from
these pathways have increased both morbidity and mortal-
ity with a three-fold increased mortality in the subgroup
of major deviations [3, 4]. Riskin and colleagues have re-
ported a reduction in mortality from 45 to 19 % after the
implementation of a massive transfusion protocol for
bleeding trauma patients in their local setting [4]. But des-
pite major improvements in resuscitation that have been
integrated into clinical trauma care, uncontrolled haemor-
rhage is still one of the leading causes of preventable death
after injury [5–8]. Therefore, the primary focus of any
treatment strategy should be related to the early detection
and control of blood loss including haemostasis. The need
for an efficient and rapid treatment of patients with un-
controlled bleeding and coagulopathy becomes evident
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since half of all trauma-related deaths occur within 6 h
of hospital admission [9, 10]. One quarter of all se-
verely injured and haemodynamically shocked patients
develop clotting abnormalities within minutes of in-
jury. This exacerbates life-threatening bleeding and is
associated with dramatically increased morbidity and
mortality [11].
Although most facilities have implemented guidelines
and protocols to quickly assess and treat trauma patients
to date, there is high diversity in clinical practice in-
cluding diagnosis of major bleeding and trauma-induced
coagulopathy [3, 4, 12–16]. These protocols may vary
depending upon local infrastructure and logistics, thus,
making outcome comparisons between individual centres
rather difficult.
The present study aims to describe the current clinical
practice management for severely bleeding trauma patients
across six central and northern European level I trauma
centres with long standing scientific expertise in the field of
coagulopathy. All centres are founding members of the
International Trauma Research Network (INTRN) and cur-
rently run the EU FP-7-funded research project “Targeted
Action to Cure Trauma-Induced Coagulopathy (TACTIC)”
which aims to deliver universal guidelines for different en-




The founding trauma centres affiliated to the INTRN
that are also involved in the EU FP-7 TACTIC project
are the Oslo University Hospital Ulleval (Oslo (OSL),
Norway), Rigshospitalet Copenhagen (Copenhagen (CPH),
Denmark), Academic Medical Centrum (Amsterdam
(AMC), The Netherlands), John Radcliffe Hospital
(Oxford (OXF), UK), Royal London Hospital (London
(RLH), UK), Cologne Merheim Medical Center, University
Witten/Herdecke (Cologne (COL), Germany) (Fig. 1).
As part of a EU FP-7 TACTIC work package (WP 3)
the present study aims to describe the current clinical
practice management for severely bleeding trauma pa-
tients across six central and northern European level I
trauma centres who are EU FP-7 TACTIC affiliated part-
ners. The participation of other centres was not taken into
account.
Online survey
An online survey was designed and programmed with
accreditation and support of the IT division of the Univer-
sity Witten/Herdecke using the Lime Survey application
(http://www.limesurvey.org/). The survey included a set of
13 questions to be answered via single or multiple-choice
answers, a drop down menu and one description field for
manual entry (Additional file 1). The link to access the
questionnaire was distributed via mail to the INTRN-site
leads of the centres mentioned above.
Massive transfusion protocols (MTPs) and algorithms
Each centre was further requested to provide their local
treatment algorithms and massive transfusions protocols
that are activated for the management of bleeding trauma
patients in their local settings.
Rigshospitalet Copenhagen  
(Copenhagen, Danmark)




Royal London Hospital 
(London, UK)
John Radcliffe Hospital  
(Oxford, UK)
Cologne-Merheim Medical Center 
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Fig. 1 INTRN-affiliated trauma centres across central and northern Europe
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Results
Characterization of the six trauma centres
Trauma centres in London and Oslo receive the greatest
number of severely injured patients (ISS ≥16) with
more than 400 patients admitted per year, followed by
Copenhagen (301–400 patients), Amsterdam and Oxford
(201–300 patients), and Cologne (101–200 patients;
Table 1). All centres declared that less than 10 % of
their patients are considered as severe, coagulopathic
bleeders requiring haemostatic therapy including a
massive transfusion. Half of the centres reported that
pre-hospital blood product administration (CPH, OSL,
and OXF) was available. In-hospital rapid administration
of blood products, mostly within less than 15 min, is facili-
tated by an in-house blood bank in all centres. All centres
provide multidisciplinary teams for the initial treatment of
bleeding trauma patients in the resuscitation room. Al-
most all reported having immediate access to standard
blood products and haemostatic agents including single
factor concentrates as shown in Table 2. The availability of
cryoprecipitate was restricted to centres in the UK and
Copenhagen. Half of the centres reported having thawed
plasma for immediate Emergency Department use (AMC,
CPH and OXF). Just one centre (OSL) indicated use of
Octaplas as Solvent/Detergent treated (virus inactivated)
pooled frozen plasma.
Assessment, diagnosis and monitoring of haemostatic
abnormalities/coagulopathy
Table 3 provides an overview of parameters and diagnostic
procedures locally in use to assess, diagnose and monitor
haemostatic abnormalities and coagulopathy in bleeding
trauma patients. The majority of the centres reported using
standard laboratory and coagulation tests (haemoglobin
(Hb), INR, quantitative fibrinogen and platelet counts)
combined with imaging (conventional X-ray ultrason-
ography and computed tomography) to rapidly assess
and monitor haemostatic disorders/coagulopathy. The
level of shock is usually determined via point-of-care
arterial blood gas (ABG) analysis providing quick informa-
tion on acid–base status, lactate and pH. Most of the
laboratory results are available within 30 min or latest
within 1 h, irrespective of centre. Half of all centres or
even fewer run functional assays such as viscoelastic
tests, aggregometry or functional fibrinogen tests. One
centre (COL) assesses patients via a scoring system pre-
dicting a massive transfusion that integrates clinical
and laboratory findings (e.g. Trauma Associated Severe
Haemorrhage (TASH)).
Local haemostasis, resuscitation and coagulation
management in case of major bleeding
Key measures in most centres in the acute phase are
control of local bleeding sources via tourniquets and
compression, the achievement and maintenance of systolic
blood pressure via crystalloid volume administration and/
or vasopressors, measures to further prevent temperature
loss and acidosis and damage control strategies (Fig. 2).
All centres recognize the importance of time management
in the initial resuscitation of bleeding and coagulopathic
trauma patients. For the initial correction of haemostatic
abnormalities and coagulopathy, standard blood products,
fibrinolysis inhibitor tranexamic acid (TXA), and coagula-
tion factor concentrates either as single factors or in
different combinations are immediately available and in
use (Table 2).
Table 1 Trauma centre characteristics
Location Amsterdam Cologne Copenhagen London Oslo Oxford
Admitted trauma patients 201–300 100–200 201–300 >400 > 400 201–300
Patients with massive bleeding [%] < 10 < 10 < 10 < 10 < 10 < 10
Pre-hospital blood administration x x x
Blood bank in-house x x x x x x
Administration first blood product [min] <15 16–30 <15 <15 <15 <15
Intended transfusion ratio 1:1:1 1:1 1:1:1 1:2 1:1:1 3:2:1
Specialities in the trauma resuscitation room
General surgery x x x
Trauma/orthopaedic surgery x x x x x
Anaesthesiology x x x x x x
Transfusion medicine x
Intensive care/critical care medicine x
Accident and emergency medicine x x x
Trauma general surgeons x x
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Treatment algorithms and massive transfusion protocols
(MTPs)
The different treatment algorithms and massive transfu-
sion protocols (MTPs) locally in use are shown in Figs. 3,
4, 5 and 6 and Additional files 2 and 3. Although differ-
ently structured, the algorithms and protocols in use
may be divided into detailed proceeding and controlling
steps, defined transfusion packages and/or viscoelastic
test-driven actions and therapeutic aims.
Activation of the algorithms/protocols
The algorithms and protocols are mostly activated ac-
cording to clinical assessment indicating (suspected) ac-
tive/uncontrolled haemorrhage and shock/hypoperfusion
combined with poor responsiveness to initial fluid resus-
citation and a continuous arterial blood pressure of
below 90 mmHg. The immediate administration of tran-
examic acid (TXA) in cases of severe trauma and/or
shock prior to any other measure or action is a principle
component within all algorithms and protocols provided.
The first blood samples are analysed for full blood count
including platelets, standard coagulation parameters (PT
and aPTT), fibrinogen and cross matching. Extended
viscoelastic testing on a routine basis is performed in
two centres (COL and CPH), and upon availability in other
centres (OXF, AMC).
Emergency transfusion
All centres provide O Rhesus negative blood units for
immediate blood transfusion and switch over to group
specific blood bags as soon as cross typing is performed.
All algorithms provided address environmental factors
further contributing and augmenting coagulopathy and
shock, such as hypothermia, acidosis, hypovolaemia and
hypocalcaemia. Likewise, all algorithms address antagon-
ism of anticoagulants such as vitamin K and heparin, if
intake is known or suspected.
Transfusion packs and ratios
Four centres (RLH, OXF, AMC, and OSL; Figs. 5 and 6
Additional files 2 and 3) work with fixed transfusion
packages delivered by the local blood banks upon algo-
rithm/protocol activation with blood products aimed to
be administered in specified ratios (Table 4). The pack-
ages differ between centres with regard to their blood
product components and three centres distinguish be-
tween two types of packages with second packs (pack B)
continuously administered in cases of ongoing bleeding
(Table 4). Apart from the first packs, which generally
contain standard universal blood products, the second
packs also usually contain coagulation factor concentrates
according to local availability, for example fibrinogen or
cryoprecipitate. A clinical and laboratory reassessment is
usually scheduled after each pack administered or at pre-





Blood products RBCs 6 100
Platelet concentrates (single platelet










Fibrinogen concentrate 5 83.3
Single factor concentrate (rFVIIa) 5 83.3
Prothrombin complex concentrate
(3- or 4-factor PCC concentrates; PPSB)
FII; FVII; FIX; FX, protein C and S
5 83.3
Single factor concentrate (FXIII) 3 50
Single factor concentrate (other) 1 16.7
Supportive
drugs
Tranexamic acid 6 100
Calcium (Ca2+) 6 100
Vitamin K 5 83.3
Aminocaproic acid 1 16.7
Table 3 Diagnostics used to rapidly assess, manage and




Laboratory tests Haemoglobin 6 100
Base excess/deficit (BE/BD) 6 100
Platelet count 5 83.3








Imaging measure FAST Ultrasound 6 100





Ionised Calcium 3 50
Viscoelastic tests (TEG/ROTEM) 3 50
Scoring Scoring systems (e.g. TASH) 1 16.7
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specified time points (OSL with blood gas analysis every
30 min and standard coagulation tests every hour until the
bleeding has stopped).
Viscoelastic test-guided algorithms in COL and CPH
Two centres (COL and CPH; Figs. 3 and 4) initiate a
transfusion package-based therapy with red blood cell
concentrates (RBCs), fresh frozen plasma (FFP) and
platelet concentrates (PTLs) (COL with RBC:FFP 1:1
and CPH with RBC:FFP:PLTs 1:1:1 (each PTL comprise
a pool of PLT from four donors)) during the initial phase of
massive bleeding and perform viscoelastic testing (either
thromboelastometry (ROTEM; COL) or thrombelastogra-
phy (TEG; CPH)) upon arrival of the patient to the trauma
bay allowing for an early shift towards a goal-directed visco-
elastic test-guided therapy subsequently. Blood samples
for viscoelastic testing, blood type and screen are obtained
immediately upon arrival to the trauma bay so these pa-
tients only receive one transfusion package with universal
blood products maximum. Viscoelastic tests are repeated
regularly depending upon the dynamics of the bleeding
and for every package administered. Hereby, restoration of
haemostasis by using adjusted doses of TXA, fibrinogen,
prothrombin complex concentrates, platelets, cryoprecipi-
tate and FFP is instituted according to the patient’s indi-
vidual viscoelastic profile.
Target values and end points of resuscitation
It is of utmost importance that algorithms and protocols
are discontinued in a timely manner, given the inherent
risk of circulatory overload resulting from rapid infusion
systems and the risk of thromboembolic events if over-
treated with blood products and haemostatic agents to a
hypercoagulable state. The aims of therapy are commonly
considered across the centres as follow:
a.) achievement of haemostasis via clinical assessment
b.) haemoglobin 8–10 g/dl
c.) PT/a PTT <1.5 × normal (OXF: PT <18 s, aPTT <36 s;
OSL: INR <1.5)
d.)platelets >50 × 109/l (RLH >80 × 109/l; OSL 100 × 109/l)
e.) Fibrinogen >1.5 g/l (RLH >1.0 g/l; OSL >2 g/l)
The therapeutic targets if viscoelastic testing is used
are depicted in the two algorithms for ROTEM and TEG
provided by the centres in Cologne (ROTEM; Fig. 3) and
Copenhagen (TEG; Fig. 4) [17, 18]. The aim of this resusci-
tation regimen is to maintain an almost normal viscoelastic
haemostatic assay (VHA) profile during the resuscitation
phase.
Discussion
The present study highlights the diversity in clinical
practice management of severe trauma haemorrhage. All
six trauma centres assessed here have developed and
implemented local algorithms and protocols for the
bleeding trauma patient and work with multidisciplinary
teams within their trauma bays as suggested by the up-
dated 2013 European guideline for the management of
bleeding and coagulopathy after major trauma [2]. There-
fore, the value of treatment algorithms in improving trauma
care but also deviations from these pathways has been
recognized [3, 4]. Within all settings, these algorithms
and protocols are uniformly activated by clinical triggers
and deactivated once the bleeding has clinically stopped
combined with laboratory signs of achieved haemostasis.
In particular the latter is of utmost importance given
the potential risks of overtransfusion and overcorrection
of haemostasis. Differences among the centres with re-
spect to laboratory targets include the level of fibrinogen
and platelets.
0 1 2 3 4 5 6
Cryoprecipitate
Body temperature (hypothermia)
Fluid resuscitation with crystalloids
Coagulation factor concentrates
Calcium
Target systolic blood pressure and vasopressor use
Local bleeding control (tourniquets, compression)
Damage control strategies (emergency surgery)
Antifibrinolytics (e.g.TXA)
Blood products (RBCs, FFPs, PTLs) inratios
Initial resuscitation and  immediate intervention
Respondents
Fig. 2 Key measures during initial resuscitation for bleeding control
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The degree of coagulopathy and shock is mostly assessed
via standard coagulation tests and ABGs. Of interest,
only four centres (only COL and CPH on a regular
basis) perform extended viscoelastic testing to assess
the severity of the coagulopathy in more detail. Early
variables of clot firmness assessed via viscoelastic
methods have been demonstrated to be good predic-
tors for the need of massive transfusion and outcome
with faster availability compared to standard coagula-
tion tests [17, 18]. The use of viscoelastic methods to
assist in characterizing the coagulopathy and in guid-
ing haemostatic therapy is emphasized by the updated
European guideline and the grade of recommendation
has been lifted from grade 2C in 2010 to grade 1C in
2013 [2].
All centres recognize the immediate use of fibrinolysis
inhibitor TXA in cases of severe trauma and/or shock
prior to any other measure or even blood sampling based
upon the results of the CRASH-2 trial [19]. In order to
provide optimum conditions for effective coagulation en-
vironmental factors are addressed by all algorithms and
protocols [20]. All centres start their initial resuscitation
by using transfusion packages with pre-fixed universal
blood product combinations immediately delivered to the
trauma bay by local blood banks. This approach follows
the concept of “damage control resuscitation” by applying
Fig. 3 Treatment algorithm of the Cologne-Merheim Medical Center (Germany)
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blood products at different pre-defined ratios to the
bleeding trauma patient [21–23]. While this concept for
bleeding trauma patients continues to be implemented
and executed around the world, some concerns about
using this approach have recently been raised, as it may
not achieve correction of either hypoperfusion or coagu-
lopathy during the acute phase of trauma haemorrhage
[24, 25]. The recently published PROPPR-trial did not
show a difference in mortality at 24 h and 30 days
among patients with severe trauma and massive bleeding
transfused with plasma, platelets and RBCs in a 1:1:1
compared to a 1:1:2 ratio [26]. If patients are overtriaged to
this concept it may also be associated with worse outcomes
[27]. As observed in the present study, transfusion packages
including applied ratios, although with a common thera-
peutic aim of stopping bleeding and correcting coagulopa-
thy, may substantially vary between centres with regard
to their composition thus making outcome comparisons
rather difficult. One avenue to provide a solution would
be further evidence in treatment of bleeding patients
and - if applicable - an adjustment of protocols [28].
Therefore, delivering universal guidelines for different
environments targeting the treatment of haemostatic
abnormalities in bleeding trauma patients which are
based on primary research and evidence is the aim of
the EU FP-7 funded TACTIC project.
Fig. 4 Treatment algorithm of the Rigshospitalet Copenhagen (Denmark)
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Two centres (COL and CPH) initially start with trans-
fusion packages but with viscoelastic tests running in
parallel to quickly allow to shift towards a viscoelastic
test-guided therapy subsequently [29, 30]. Via this ap-
proach the patients receive one unguided transfusion
package with universal blood products at maximum in
the acute phase and may thus be prevented from over-
transfusion and the potentially harmful effects of allogenic
blood products [31–33]. The overall and targeted aim of
this approach is to maintain as normal viscoelastic profiles
as possible during the resuscitation phase, given that
hypocoagulable profiles have repeatedly been associated
with increased mortality [30, 34].
The optimum way to resuscitate bleeding trauma pa-
tients remains unclear and, as shown in the present study,
diversity in clinical practice management exists even
across major level I centres. Although it may be likely that
goal-directed viscoelastic test-guided haemostatic resusci-
tation is superior over unguided administration of transfu-
sion packages aiming for the administration of pre-fixed
ratios of universal blood products, data from prospective,
randomized clinical trials that support either approach are
Fig. 5 “Code Red” treatment algorithm of the Royal London Hospital (UK)
Schäfer et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2015) 23:74 Page 8 of 11
Fig. 6 Transfusion management protocol of the John Radcliffe Hospital in Oxford (UK)
Table 4 Transfusion packages per centre
Amsterdam Cologne Copenhagen London Oslo Oxford
Pack A 6 × RBC 4 × RBC 5 × RBC RBCs 5 × RBC 6 × RBC
6 × FFP 4 × FFP 5 × FFP 4 × FFP 5 × Octaplas 4 × FFP
2 × 5 Platelets 2 × Platelets 1 × Platelets
Pack B 2 g Fibrinogen 4 × FFP 6 × RBC
1 × 5 Platelets 1 × Platelets 4 × FFP
100 mg/kg FVIIa 2 × Cryo 1 × Platelets
2 × Cryo
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still lacking. The authors expect to start such a trial in
2015 in context of the recently EU FP-7 funded TACTIC
project which involves the six trauma centres also involved
in the present study.
Due to the small number of centres participating the
results of this study should be regarded as expert opinion,
which therefore is limiting the expressiveness of the
findings presented.
Conclusions
This study offers valuable information about similarities
and differences in the acute treatment of bleeding patients
in six different trauma centres across central and northern
Europe. With regard to limitations of this analysis of a
questionnaire and different transfusion protocols accord-
ingly, the results presented show that in all centres algo-
rithms for the acute treatment do exist. Although
recommended in the updated European guidelines even in
the participating centres viscoelastic guided therapy and
pre-hospital blood administration cannot be regarded
as standard approach.
Thus, this study underlines the importance of further
primary research followed by clinical trials to improve the
evidence for sophisticated guidelines, which is a future
aim of the EU FP-7 TACTIC project.
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